|
All Releases
 |
Achillion to Present at Upcoming Investor Conferences
Mar 5, 2010
|
9.4 KB |
|
| |
NEW HAVEN, Conn., Mar 5, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer, will be presenting a company overview at the u...
|
|
Achillion Announces Positive 96-Week Data for Elvucitabine at the 17th Annual Conference on Retroviruses and Opportunistic Infections
Feb 17, 2010
|
13.0 KB |
|
| |
NEW HAVEN, Conn., Feb 17, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the presentation of additional positive safety and efficacy results from its Phase 2 trial stud...
|
|
Achillion to Present at 12th Annual BIO CEO and Investor Conference
Feb 8, 2010
|
9.1 KB |
|
| |
NEW HAVEN, Conn., Feb 8, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer, will present a corporate and clinical update a...
|
|
Achillion Announces Closing of Underwriters' Over-Allotment Option
Feb 2, 2010
|
9.9 KB |
|
| |
NEW HAVEN, Conn., Feb 2, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that it closed the sale of an additional 1,541,250 shares of its common stock in connection with the exercise of...
|
|
Achillion Announces License Agreement for Elvucitabine Development in China
Feb 1, 2010
|
14.0 KB |
|
| |
NEW HAVEN, Conn., Feb 1, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the execution of a license agreement for elvucitabine, the Company's nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of both hepatitis B virus (HBV) infection and human immunodeficiency virus (HI...
|
|
Achillion Announces Nomination of ACH-2684 as Lead Clinical Candidate in Resistance-Focused HCV Program
Jan 28, 2010
|
13.0 KB |
|
| |
NEW HAVEN, Conn., Jan 28, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the nomination of a lead clinical candidate in its third proprietary program against hepatitis C infection. The candidate, ACH-2684, demonstrates excellent potency in the low pico-molar range, as well as good pharm...
|
|
Achillion to Host Corporate and Clinical Update Conference Call on Monday, February 1, 2010
Jan 25, 2010
|
12.2 KB |
|
| |
NEW HAVEN, Conn., Jan 25, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, Achillion's President and Chief Executive Officer, will lead the Com...
|
|
Achillion Prices $21.4 Million Public Offering of Common Stock
Jan 22, 2010
|
11.5 KB |
|
| |
NEW HAVEN, Conn., Jan 22, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that it has priced a firm commitment underwritten public offering of 10,275,000 shares of its common stock at p...
|
|
Achillion Announces Proposed Public Offering of Common Stock
Jan 21, 2010
|
11.4 KB |
|
| |
NEW HAVEN, Conn., Jan 21, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that it intends to offer, subject to market, regulatory and other conditions, shares of its common stock in an ...
|
|
Achillion Announces Additional Positive Phase 1b Data With ACH-1625 to Treat Hepatitis C
Jan 11, 2010
|
13.8 KB |
|
| |
NEW HAVEN, Conn., Jan 11, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported additional preliminary data from its on-going phase 1b clinical trial of ACH-1625 which demonstrated that the second dosing cohort receiving treatment with ACH-1625 achieved a mean 4.25 log10 reduction in HCV RNA af...
|
|
Achillion Announces Positive Preliminary Phase 1b Proof of Concept Data With ACH-1625 to Treat Hepatitis C
Dec 15, 2009
|
15.1 KB |
|
| |
NEW HAVEN, Conn., Dec 15, 2009 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported proof of concept data from the preliminary results of its phase 1b clinical trial of ACH-1625, demonstrating that treatment with ACH-1625 achieved a mean 3.94 log10 reduction in HCV RNA after five-day monotherapy, w...
|
|
Achillion Regains Compliance With Nasdaq Listing Rules
Dec 15, 2009
|
8.9 KB |
|
| |
NEW HAVEN, Conn., Dec 15, 2009 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported that it received notification from the NASDAQ Listings Qualification Department that it has rega...
|
|
Achillion Receives Notice From NASDAQ
Nov 17, 2009
|
9.3 KB |
|
| |
NEW HAVEN, Conn., Nov 17, 2009 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported that it received notification from the NASDAQ Listings Qualification Department that the Company...
|
|
Achillion Reports Third Quarter Results
Nov 6, 2009
|
16.0 KB |
|
| |
NEW HAVEN, Conn., Nov 6, 2009 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and nine months ended September 30, 2009. For the third quarter o...
|
|
Achillion to Present at Three Upcoming Conferences
Oct 29, 2009
|
9.3 KB |
|
| |
NEW HAVEN, Conn., Oct 29, 2009 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer, will give a corporate overvie...
|
|
Achillion Completes Phase 1a Trial of ACH-1625; Begins Dosing in Phase 1b Segment With HCV-Infected Patients
Sep 28, 2009
|
13.4 KB |
|
| |
NEW HAVEN, Conn., Sep 28, 2009 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that the Company has completed Phase 1a of its ongoing clinical trial of ACH-1625, a protease i...
|
|
Achillion to Present At the Thomas Weisel Partners Annual Healthcare Conference
Sep 3, 2009
|
9.4 KB |
|
| |
NEW HAVEN, Conn., Sep 3, 2009 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer, will give a corporate presenta...
|
|
Achillion to Present At the Canaccord Adams 29th Annual Global Growth Conference
Aug 3, 2009
|
9.4 KB |
|
| |
NEW HAVEN, Conn., Aug 3, 2009 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer, will give a corporate presenta...
|
|
Achillion Reports Second Quarter and Six Month Financial Results
Jul 30, 2009
|
17.1 KB |
|
| |
NEW HAVEN, Conn., Jul 30, 2009 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and six months ended June 30, 2009. For the second quarter of 20...
|
|
Achillion Enters $15 Million Standby Equity Distribution Agreement
Jul 6, 2009
|
11.8 KB |
|
| |
NEW HAVEN, Conn., Jul 6, 2009 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that it has entered into a standby equity distribution agreement ("SEDA") with YA Global Master ...
|
|
|
= add release to Briefcase |